Systemic Therapy Fundamentals: Back to the Basics... and Beyond

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Sudish Murthy, MD, PhD
Disclosure(s): Arthrex: Consultant (Ongoing); Intuitive: Consultant (Ongoing); Medtronic: Consultant (Ongoing); ontarget laboratories: Advisory Board (Ongoing)

Jessica Donington, MD
Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)

Presentations

  1. IO 101—How Do They Work?
    Sandip Patel, MD
    Disclosure(s): Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Signatera, Tempus: Advisory Board (Terminated); Amgen, AstraZeneca, A2bio, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated)
     
  2. Discussion
     
  3. IO 102—Application to Clinical Practice
    Olugbenga Tokunbo Okusanya, MD
    Disclosure(s): Astrazeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atricure: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ethicon Endosurgery: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  4. Discussion
     
  5. Targeted Therapy 101—How Does it Work?
    Narjust Florez, MD FASCO
    Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing); Daiichi-Sankyo: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Merck & Co.: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Advisory Board (Terminated); Novocure: Advisory Board (Ongoing); Pfizer: Advisory Board (Ongoing), Consultant (Ongoing)
     
  6. Discussion
     
  7. Targeted Therapy 102—Application to Clinical Practice
    Ravi Rajaram, MD, MSc
    Disclosure(s): Cook Medical: Consultant (Terminated); Intuitive Surgical: Proctor (Ongoing); Johnson & Johnson: Consultant (Ongoing)
     
  8. Discussion
     
  9. Chemotherapy for Lung Cancer in 2025
    Janet Tu, MD
     
  10. Discussion
Activity summary
Available credit: 
  • 1.00 ABS Accredited CME
  • 1.00 ABTS Accredited CME
  • 1.00 AMA PRA Category 1 Credit
Activity opens: 
03/01/2025
Activity expires: 
03/01/2028
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 ABS Accredited CME
  • 1.00 ABTS Accredited CME
  • 1.00 AMA PRA Category 1 Credit

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Sudish Murthy, MD, PhD
Disclosure(s): Arthrex: Consultant (Ongoing); Intuitive: Consultant (Ongoing); Medtronic: Consultant (Ongoing); ontarget laboratories: Advisory Board (Ongoing)

Jessica Donington, MD
Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)

Presentations

  1. IO 101—How Do They Work?
    Sandip Patel, MD
    Disclosure(s): Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Signatera, Tempus: Advisory Board (Terminated); Amgen, AstraZeneca, A2bio, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated)
     
  2. Discussion
     
  3. IO 102—Application to Clinical Practice
    Olugbenga Tokunbo Okusanya, MD
    Disclosure(s): Astrazeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atricure: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ethicon Endosurgery: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  4. Discussion
     
  5. Targeted Therapy 101—How Does it Work?
    Narjust Florez, MD FASCO
    Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing); Daiichi-Sankyo: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Merck & Co.: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Advisory Board (Terminated); Novocure: Advisory Board (Ongoing); Pfizer: Advisory Board (Ongoing), Consultant (Ongoing)
     
  6. Discussion
     
  7. Targeted Therapy 102—Application to Clinical Practice
    Ravi Rajaram, MD, MSc
    Disclosure(s): Cook Medical: Consultant (Terminated); Intuitive Surgical: Proctor (Ongoing); Johnson & Johnson: Consultant (Ongoing)
     
  8. Discussion
     
  9. Chemotherapy for Lung Cancer in 2025
    Janet Tu, MD
     
  10. Discussion